Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Commitments and Contingencies (Details Textual)

v3.19.2
Note 11 - Commitments and Contingencies (Details Textual)
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 18, 2019
Aug. 14, 2018
Apr. 09, 2018
USD ($)
Jan. 16, 2018
USD ($)
Mar. 03, 2017
USD ($)
Nov. 30, 2018
shares
Dec. 31, 2017
USD ($)
Nov. 30, 2017
USD ($)
Jun. 30, 2019
USD ($)
$ / shares
shares
Mar. 31, 2019
shares
Jun. 30, 2019
USD ($)
$ / shares
Apr. 26, 2019
$ / shares
Dec. 31, 2018
USD ($)
$ / shares
Aug. 31, 2018
shares
Jun. 30, 2018
USD ($)
$ / shares
Stockholders' Equity Attributable to Parent, Ending Balance                 $ 2,263,201   $ 2,263,201   $ 1,742,139   $ 2,100,000
Common Stock, Par or Stated Value Per Share | $ / shares                 $ 0.001   $ 0.001 $ 0.001 $ 0.001   $ 0.001
Reverse Stock Split [Member]                              
Stockholders' Equity Note, Stock Split, Conversion Ratio 20                            
Common Stock [Member]                              
Stock Issued During Period, Shares, New Issues | shares                 8,000,000 17,857          
Former Chief Executive Officer and President [Member]                              
Common Stock Shares Provided by Agreement | shares                           1,175,000  
Common Stock Shares Provided by Agreement, Escrow Period   1 year 180 days                          
Former Chief Executive Officer and President [Member] | Common Stock [Member]                              
Stock Issued During Period, Shares, New Issues | shares           925,000                  
Stock Issued During Period, Shares, New Issues Placed in Escrow | shares           250,000                  
Former Chief Executive Officer and President [Member] | MT [Member] | Common Stock [Member] | Dr. Michael Goldberg [Member]                              
Ownership Percentage                 5.00%   5.00%        
Maximum [Member] | Reverse Stock Split [Member]                              
Stockholders' Equity Note, Stock Split, Conversion Ratio 20                            
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]                              
Loss Contingency, Damages Awarded, Value, Additional Amount             $ 7,000,000                
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration             4,100,000       $ 4,100,000        
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | Term Loan Agreement [Member]                              
Repayments of Debt     $ 7,100,000                        
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | CRG [Member] | Term Loan Agreement [Member]                              
Repayments of Debt             59,000,000                
Platinum-Montaur Life Sciences LLC Litigation [Member]                              
Loss Contingency, Damages Sought, Value               $ 1,900,000              
Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member]                              
Loss Contingency, Damages Sought, Value               $ 1,900,000              
Texas Court Judgement Appeal [Member]                              
Loss Contingency, Damages Sought, Value       $ 4,100,000                      
CRG [Member] | CRG Loan Agreement, Texas Case [Member] | Minimum [Member]                              
Litigation Settlement, Amount Awarded to Other Party             $ 66,000,000                
CRG [Member] | Global Settlement Agreement [Member] | Maximum [Member]                              
Litigation Settlement, Amount Awarded to Other Party         $ 66,000,000